DOAJ Open Access 2022

Antiplatelet Therapy for Atherothrombotic Disease in 2022—From Population to Patient-Centered Approaches

Georges Jourdi Georges Jourdi Anne Godier Anne Godier Marie Lordkipanidzé +5 lainnya

Abstrak

Antiplatelet agents, with aspirin and P2Y12 receptor antagonists as major key molecules, are currently the cornerstone of pharmacological treatment of atherothrombotic events including a variety of cardio- and cerebro-vascular as well as peripheral artery diseases. Over the last decades, significant changes have been made to antiplatelet therapeutic and prophylactic strategies. The shift from a population-based approach to patient-centered precision medicine requires greater awareness of individual risks and benefits associated with the different antiplatelet strategies, so that the right patient gets the right therapy at the right time. In this review, we present the currently available antiplatelet agents, outline different management strategies, particularly in case of bleeding or in perioperative setting, and develop the concept of high on-treatment platelet reactivity and the steps toward person-centered precision medicine aiming to optimize patient care.

Penulis (10)

G

Georges Jourdi

G

Georges Jourdi

A

Anne Godier

A

Anne Godier

M

Marie Lordkipanidzé

M

Marie Lordkipanidzé

G

Guillaume Marquis-Gravel

G

Guillaume Marquis-Gravel

P

Pascale Gaussem

P

Pascale Gaussem

Format Sitasi

Jourdi, G., Jourdi, G., Godier, A., Godier, A., Lordkipanidzé, M., Lordkipanidzé, M. et al. (2022). Antiplatelet Therapy for Atherothrombotic Disease in 2022—From Population to Patient-Centered Approaches. https://doi.org/10.3389/fcvm.2022.805525

Akses Cepat

PDF tidak tersedia langsung

Cek di sumber asli →
Lihat di Sumber doi.org/10.3389/fcvm.2022.805525
Informasi Jurnal
Tahun Terbit
2022
Sumber Database
DOAJ
DOI
10.3389/fcvm.2022.805525
Akses
Open Access ✓